Who is sponsoring NCT07086534?

NCT07086534 is sponsored by Sierra Valve LLC.

What drugs are being tested in NCT07086534?

Interventions in NCT07086534: GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System.

What condition does NCT07086534 study?

NCT07086534 studies Mitral Regurgitation.

Is NCT07086534 still recruiting?

NCT07086534 is currently not yet recruiting. Last updated 25 July 2025.

Last reviewed 2025-07-25 · How we verify

NCT07086534

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study of GeminiOne TEER System for the Treatment of Severe, Symptomatic MR.

Not yet recruiting NA Last updated 25 July 2025

What this trial tests

NA trial testing GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System in Mitral Regurgitation in 15 participants. Not yet recruiting.

Timeline

15 December 2025

Primary endpoint
30 April 2026

31 May 2031

Quick facts

Lead sponsor	Sierra Valve LLC
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	15 December 2025
Primary completion	30 April 2026
Estimated completion	31 May 2031

Drugs / interventions tested

GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System

Conditions studied

Mitral Regurgitation — all drugs for Mitral Regurgitation →

Sponsor

Sierra Valve LLC

Who can join

18 and older, any sex, with Mitral Regurgitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To confirm the effectiveness and safety of the GeminiOne Transcatheter Mitral Valve Repair System for the treatment of severe, symptomatic mitral regurgitation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mitral Regurgitation

Currently open trials in the same condition.

NCT07450911 — A Clinical Study Evaluating the Replacement of the Native Mitral Valve Using the ReValve System · Phase 1 · recruiting
NCT07366723 — The Role of cardIac magNeTic rEsonance in surGical Decision Making in Patients With Severe pRimAry miTral rEgurgitation · NA · active not recruiting
NCT07007143 — STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication fo · Phase 4 · recruiting
NCT07108907 — Outcome Registry and Assessment of New Edge-to-Edge Repair · recruiting
NCT06901466 — STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for O · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07086534 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sierra Valve LLC
Last refreshed: 25 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07086534.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing